Cytoreductive nephrectomy in metastatic renal cell carcinoma

References

• Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med.353(23), 2477–2490 (2005).
   PubMed Web of Science ®Google Scholar
• Yonover PM, Flanigan RC. Should radical nephrectomy be performed in the face of surgically incurable disease? Curr. Opin. Urol.10(5), 429–434 (2000).
   PubMedGoogle Scholar
• Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr. Treat. Options Oncol.4(5), 385–390 (2003).
   PubMedGoogle Scholar
• Mickisch GH, Mattes RH. Combination of surgery and immunotherapy in metastatic renal cell carcinoma. World J. Urol.23(3), 191–195 (2005).
   PubMed Web of Science ®Google Scholar
• Sengupta S, Leibovich BC, Blute ML, Zincke H. Surgery for metastatic renal cell cancer. World J. Urol.23(3), 155–160 (2005).
   PubMed Web of Science ®Google Scholar
• Weiss G. Immunotherapy of renal cell carcinoma. Contemporary Urol.DOI: 10.1007/s00262-006-0172-4 (2005) (Epub ahead of print).
   Google Scholar
• Figlin RA. Renal cell carcinoma: management of advanced disease. J. Urol.161(2), 381–386 (1999).
   PubMed Web of Science ®Google Scholar
• Rohrmann K, Staehler M, Haseke N, Bachmann A, Stief CG, Siebels M. Immunotherapy in metastatic renal cell carcinoma. World J. Urol.23(3), 196–201 (2005).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol.163(2), 408–417 (2000).
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol.13(3), 688–696 (1995).
   PubMed Web of Science ®Google Scholar
• Lam JS, Belldegrun AS, Figlin RA. Advances in immune-based therapies of renal cell carcinoma. Expert Rev. Anticancer Ther.4(6), 1081–1096, (2004).
   PubMedGoogle Scholar
• Lopez HE, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J. Urol.155(1), 19–25 (1996).
   PubMed Web of Science ®Google Scholar
• Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol.21(16), 3127–3132 (2003).
   PubMed Web of Science ®Google Scholar
• Schomburg A, Kirchner H, Atzpodien J. Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon α: evidence of a risk/benefit advantage of subcutaneous therapy. J. Cancer Res. Clin. Oncol.119(12), 745–755 (1993).
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon α-2a in metastatic renal cancer: an outpatient multicenter trial. J. Clin. Oncol.11(9), 1809–1816 (1993).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol.23(1), 133–141, (2005).
   PubMed Web of Science ®Google Scholar
• Bui MH, Visapaa H, Seligson D et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J. Urol.71(6 Pt 1), 2461–2466 (2004).
   Google Scholar
• Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res.11(10), 3714–3721 (2005).
   PubMed Web of Science ®Google Scholar
• Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J. Urol.158(5), 1691–1695 (1997).
   PubMed Web of Science ®Google Scholar
• Walther MM, Alexander RB, Weiss GH et al. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology42(3), 250–257 (1993).
   PubMed Web of Science ®Google Scholar
• Robertson CN, Linehan WM, Pass HI et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J. Urol.144(3), 614–617 (1990).
   PubMed Web of Science ®Google Scholar
• Flanigan RC. Debulking nephrectomy in metastatic renal cancer. Clin. Cancer Res.10(18 Pt 2), S6335–S6341 (2004).
   Google Scholar
• Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet358(9286), 966–970 (2001).
   PubMed Web of Science ®Google Scholar
• Wood CG. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urologic Clin. N. Am.30(3), 581–588 (2003).
   PubMed Web of Science ®Google Scholar
• Freed SZ, Halperin JP, Gordon M. Idiopathic regression of metastases from renal cell carcinoma. J. Urol.118(4), 538–542 (1977).
   PubMed Web of Science ®Google Scholar
• Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer80(7), 1198–1220 (1997).
   PubMed Web of Science ®Google Scholar
• Sella A, Swanson DA, Ro JY et al. Surgery following response to interferon-α-based therapy for residual renal cell carcinoma. J. Urol.149(1), 19–21 (1993).
   PubMed Web of Science ®Google Scholar
• Rackley R. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J. Urol.152(5 Pt 1), 1399–1403 (1994).
   PubMed Web of Science ®Google Scholar
• Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA, Yang JC. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J. Urol.162(1), 43–45 (1999).
   PubMed Web of Science ®Google Scholar
• Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J. Urol.154(1), 35–40 (1995).
   PubMed Web of Science ®Google Scholar
• Figlin RA, Pierce WC, Kaboo R et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8+ selected tumor infiltrating lymphocytes from primary tumor. J. Urol.158(3 Pt 1), 740–745 (1997).
   PubMed Web of Science ®Google Scholar
• Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J. Urol.158(5), 1675–1678 (1997).
   PubMed Web of Science ®Google Scholar
• Tigrani VS, Reese DM, Small EJ, Presti JC, Carroll PR. Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis. Urology55(1), 36–40 (2000).
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N. Engl. J. Med.345(23), 1711–1712 (2001).
   PubMed Web of Science ®Google Scholar
• Mosharafa A, Koch M, Shalhav A et al. Nephrectomy for metastatic renal cell carcinoma: Indiana University experience. Urology62(4), 636–640 (2003).
   PubMed Web of Science ®Google Scholar
• Wolf JS Jr, Aronson FR, Small EJ, Carroll PR. Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J. Surg. Oncol.55(1), 7–13 (1994).
   PubMed Web of Science ®Google Scholar
• Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J. Cytoreductive surgery for stage IV renal cell carcinoma. J. Urol.154(1), 32–34 (1995).
   PubMed Web of Science ®Google Scholar
• Franklin JR, Figlin R, Rauch J, Gitlitz B, Belldegrun A. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Semin. Urologic Oncol.14(4), 230–236 (1996).
   PubMedGoogle Scholar
• Levy DA, Swanson DA, Slaton JW, Ellerhorst J, Dinney CP. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J. Urol.159(4), 1168–1173 (1998).
   PubMed Web of Science ®Google Scholar
• Wood CG, Madsen L, Fortner C, Ramirez E, Swanson DA. Clinical variables that predict survival following cytoreductive nephrectomy for metastatic renal cell carcinoma. J. Urol.165(5), 184A (2001).
   Google Scholar
• Clayman RV, Kavoussi LR, Soper NJ et al. Laparoscopic nephrectomy: initial case report. J. Urol.146(2), 278–282 (1991).
   PubMed Web of Science ®Google Scholar
• Dunn MD, Portis AJ, Shalhav AL et al. Laparoscopic versus open radical nephrectomy: a 9-year experience. J. Urol.164(4), 1153–1159 (2000).
   PubMed Web of Science ®Google Scholar
• McDougall E, Clayman RV, Elashry OM. Laparoscopic radical nephrectomy for renal tumor: the Washington University experience. J. Urol.155(4), 1180–1185 (1996).
   PubMed Web of Science ®Google Scholar
• Walther MM, Lyne JC, Libutti SK, Linehan WM. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology53(3), 496–501 (1999).
   PubMed Web of Science ®Google Scholar
• Finelli A, Kaouk JH, Fergany AF, Abreu SC, Novick AC, Gill IS. Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma. Br. J. Urol. Int.94(3), 291–294 (2004).
   Google Scholar
• Rabets JC, Kaouk J, Fergany A, Finelli A, Gill IS, Novick AC. Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology64(5), 930–934 (2004).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med.345(23), 1655–1659 (2001).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol.171(3), 1071–1076 (2004).
   PubMed Web of Science ®Google Scholar
• Kirkali Z, Tuzel E, Mungan MU. Recent advances in kidney cancer and metastatic disease. Br. J. Urol. Int.88(8), 818–824 (2001).
   Google Scholar
• Krishnamurthi V, Novick AC, Bukowski RM. Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology51(6), 933–937 (1998).
   PubMed Web of Science ®Google Scholar
• Kim B, Louie AC. Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch. Surg.127(11), 1343–1349 (1992).
   PubMedGoogle Scholar
• Bex A, Horenblas S, Meinhardt W, Verra N, de Gast GC. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ.Eur. Urol.42(6), 570–574 (2002).
   PubMed Web of Science ®Google Scholar
• Mejean A, Roupret M, Larousserie F, Hopirtean V, Thiounn N, Dufour B. Is there a place for radical nephrectomy in the presence of metastatic collecting duct (Bellini) carcinoma? J. Urol.169(4), 1287–1290 (2003).
   PubMed Web of Science ®Google Scholar
• Slaton JW, Balbay PP. Reassessment of the selection criteria for cytoreductive nephrectomy for metastatic renal cell carcinoma. J. Urol.163(Suppl. 4), 79 (2000).
   PubMed Web of Science ®Google Scholar
• Han KR, Pantuck AJ, Bui MH et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology61(2), 314–319 (2003).
   PubMed Web of Science ®Google Scholar
• Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J. Urol.23(3), 202–212 (2005).
   PubMed Web of Science ®Google Scholar
• Favaro JP, George DJ. Targeted therapy in renal cell carcinoma. Expert Opin. Invest. Drugs14(10), 1251–1258 (2005).
   PubMed Web of Science ®Google Scholar
• Staehler M, Rohrmann K, Haseke N, Stief CG, Siebels M. Targeted agents for the treatment of advanced renal cell carcinoma. Curr. Drug Targets6(7), 835–846 (2005).
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol.24(1), 25–35 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24(1), 16–24 (2006).
   PubMed Web of Science ®Google Scholar